Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism

Amgen Inc. (NASDAQ:AMGN) is included among the 10 Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026.

Amgen (AMGN) Gets Price Target Cut at Piper Sandler Despite Long-Term Growth Optimism

On May 14, Piper Sandler lowered its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $427 from $432. It reiterated an Overweight rating on the stock. The firm said that, from a broader business perspective, it still sees potential upside to consensus revenue estimates not only for 2026 but also for 2027. Analysts noted that this outlook is less tied to the company’s core commercial products and more driven by continued momentum in the rare disease segment, especially Uplizna. Piper also pointed to Tepezza as a possible long-term growth driver following strong Phase III results for its subcutaneous formulation.

A week earlier, on May 7, Freedom Broker upgraded Amgen to Buy from Hold and kept its price target unchanged at $375.The firm said Amgen’s first-quarter results were “fully in line with our expectations, although the quarter is seasonally weak.” Analysts added that it is “still too early to draw firm conclusions about the earnings trajectory for the full year,” though the company’s main growth drivers remain in place. Following the stock’s decline in the first quarter and the steady performance of Amgen’s innovative portfolio, which has helped offset weakness in mature products, the firm decided to upgrade the shares.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and delivers medicines targeting serious diseases. The company focuses on areas with high unmet medical needs and uses its scientific expertise to develop treatments aimed at improving patients’ lives. It operates through the human therapeutics segment.

While we acknowledge the risk and potential of AMGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 12 Best Micro-Cap Dividend Stocks To Buy Now and 11 Best Rising Dividend Stocks to Buy Right Now

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1